POINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? Yes

Affiliations

¹ Hannover Medical School and Deutsches Zentrum für Lungenforschung (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany. Electronic address: prasse.antje@mh-hannover.de.

Editorial

Antje Prasse. Chest. 2019 Aug.

. 2019 Aug;156(2):203-205.

doi: 10.1016/j.chest.2019.03.026.

¹ Hannover Medical School and Deutsches Zentrum für Lungenforschung (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany. Electronic address: prasse.antje@mh-hannover.de.

No abstract available

Comment in

Rebuttal From Dr Ley.
Ley B. Ley B. Chest. 2019 Aug;156(2):209-210. doi: 10.1016/j.chest.2019.03.028. Chest. 2019. PMID: 31395258 No abstract available.
A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease.
Raghu G, Colby TV, Myers JL, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Hagmeyer L, Davis JR, Bhorade SM, Kennedy GC, Gauher UA, Martinez FJ. Raghu G, et al. Chest. 2020 May;157(5):1391-1392. doi: 10.1016/j.chest.2019.10.061. Chest. 2020. PMID: 32386639 No abstract available.